{"id":59759,"date":"2024-07-26T13:04:20","date_gmt":"2024-07-26T11:04:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/"},"modified":"2024-07-26T13:04:20","modified_gmt":"2024-07-26T11:04:20","slug":"agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/","title":{"rendered":"Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update"},"content":{"rendered":"
\n

LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (\u201cAgenus\u201d) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.<\/p>\n

<\/a>
<\/a><\/p>\n

\nConference Call:<\/span><\/b><\/p>\n

\nTo access dial-in numbers, please register here<\/a>.<\/p>\n

\nConference ID: 73242<\/p>\n

\nA live webcast and replay of the conference call will be accessible on the company\u2019s website at https:\/\/investor.agenusbio.com\/events-and-presentations<\/a>.<\/p>\n

\nAbout Agenus<\/b><\/p>\n

\nAgenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com<\/a> or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.<\/p>\n

\nForward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding a its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words “may,” “believes,” “expects,” “anticipates,” “hopes,” “intends,” “plans,” “forecasts,” “estimates,” “will,” \u201cestablish,\u201d \u201cpotential,\u201d \u201csuperiority,\u201d \u201cbest in class,\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2022, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors<\/b>
917-362-1370
\n
investor@agenusbio.com<\/a><\/p>\n

\nMedia<\/b>
612-839-6748
\n
communications@agenusbio.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (\u201cAgenus\u201d) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59759","6":"format-standard","7":"category-industry"},"yoast_head":"\nAgenus to Provide Second Quarter 2024 Financial Report and Corporate Update - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (\u201cAgenus\u201d) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-26T11:04:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240726475067\/en\/381089\/5\/2_Agenus-Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update\",\"datePublished\":\"2024-07-26T11:04:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\\\/\"},\"wordCount\":414,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240726475067\\\/en\\\/381089\\\/5\\\/2_Agenus-Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\\\/\",\"name\":\"Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240726475067\\\/en\\\/381089\\\/5\\\/2_Agenus-Logo.jpg\",\"datePublished\":\"2024-07-26T11:04:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240726475067\\\/en\\\/381089\\\/5\\\/2_Agenus-Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240726475067\\\/en\\\/381089\\\/5\\\/2_Agenus-Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update - Pharma Trend","og_description":"LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (\u201cAgenus\u201d) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/","og_site_name":"Pharma Trend","article_published_time":"2024-07-26T11:04:20+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240726475067\/en\/381089\/5\/2_Agenus-Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update","datePublished":"2024-07-26T11:04:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/"},"wordCount":414,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240726475067\/en\/381089\/5\/2_Agenus-Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/","url":"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/","name":"Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240726475067\/en\/381089\/5\/2_Agenus-Logo.jpg","datePublished":"2024-07-26T11:04:20+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240726475067\/en\/381089\/5\/2_Agenus-Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240726475067\/en\/381089\/5\/2_Agenus-Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/agenus-to-provide-second-quarter-2024-financial-report-and-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59759"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59759\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}